Shots:

• GSK highlighted complete results from the P-III (SWIFT-1 & SWIFT-2) studies at ERS 2024 and published it in the NEJM
• The P-III trials for depemokimab in severe asthma includes SWIFT-1, SWIFT-2 & an OLE AGILE studies, with SWIFT-1 & 2 evaluating it as an adjunctive therapy vs PBO in patients (n=382 & n=380) with type 2 inflammation. Another NIMBLE trial is ongoing in those switching from mepolizumab/benralizumab
• Both trials reached the 1EPs, showing a 54% reduction in the annualized rate of asthma exacerbations at 52wks.; pooled analysis revealed a 72% reduction in exacerbations requiring hospitalization or emergency visits. 2EPs of QoL were improved but not significant. Data will form the basis of regulatory filings

Ref: GSK | Image: GSK

Related News: GSK Reports Results from the P-III (SWIFT-1 and SWIFT-2) Studies of Depemokimab for Treating Severe Asthma

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com